DK2505204T3 - Fremgangsmåde til behandling af prostatakræft med GnRH-antagonisten degarelix - Google Patents

Fremgangsmåde til behandling af prostatakræft med GnRH-antagonisten degarelix Download PDF

Info

Publication number
DK2505204T3
DK2505204T3 DK12165896T DK12165896T DK2505204T3 DK 2505204 T3 DK2505204 T3 DK 2505204T3 DK 12165896 T DK12165896 T DK 12165896T DK 12165896 T DK12165896 T DK 12165896T DK 2505204 T3 DK2505204 T3 DK 2505204T3
Authority
DK
Denmark
Prior art keywords
prostate cancer
treating prostate
gnrh antagonist
antagonist degarelix
degarelix
Prior art date
Application number
DK12165896T
Other languages
Danish (da)
English (en)
Inventor
Tine Kold Olesen
Bo-Eric Persson
Per Cantor
Der Meulen Egbert A Van
Jens-Christian Slott Jensen
Original Assignee
Ferring Bv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=39718285&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK2505204(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Ferring Bv filed Critical Ferring Bv
Application granted granted Critical
Publication of DK2505204T3 publication Critical patent/DK2505204T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A61K38/09—Luteinising hormone-releasing hormone [LHRH], i.e. Gonadotropin-releasing hormone [GnRH]; Related peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Reproductive Health (AREA)
  • Endocrinology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Dermatology (AREA)
  • Oncology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
DK12165896T 2008-02-11 2009-02-10 Fremgangsmåde til behandling af prostatakræft med GnRH-antagonisten degarelix DK2505204T3 (da)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US2774108P 2008-02-11 2008-02-11
EP08250703 2008-02-29
EP09709538A EP2249858A1 (en) 2008-02-11 2009-02-10 Method of treating prostate cancer with the gnrh antagonist degarelix

Publications (1)

Publication Number Publication Date
DK2505204T3 true DK2505204T3 (da) 2015-03-16

Family

ID=39718285

Family Applications (3)

Application Number Title Priority Date Filing Date
DK12165896T DK2505204T3 (da) 2008-02-11 2009-02-10 Fremgangsmåde til behandling af prostatakræft med GnRH-antagonisten degarelix
DK13168404.5T DK2650012T3 (da) 2008-02-11 2009-02-10 Behandling af prostatacancer i metastasestadium med degarelix.
DK09711390.6T DK2249859T3 (da) 2008-02-11 2009-02-10 Behandling af metastatisk prostatacancer med degarelix

Family Applications After (2)

Application Number Title Priority Date Filing Date
DK13168404.5T DK2650012T3 (da) 2008-02-11 2009-02-10 Behandling af prostatacancer i metastasestadium med degarelix.
DK09711390.6T DK2249859T3 (da) 2008-02-11 2009-02-10 Behandling af metastatisk prostatacancer med degarelix

Country Status (25)

Country Link
US (17) US8841081B2 (enExample)
EP (7) EP2249858A1 (enExample)
JP (11) JP5876652B2 (enExample)
KR (8) KR20140130757A (enExample)
CN (4) CN101998861A (enExample)
AU (2) AU2009213751B2 (enExample)
BR (2) BRPI0908127A2 (enExample)
CA (3) CA3235099A1 (enExample)
CY (3) CY1115561T1 (enExample)
DK (3) DK2505204T3 (enExample)
EA (4) EA036695B1 (enExample)
ES (3) ES2479441T3 (enExample)
HK (1) HK1198243A1 (enExample)
HR (3) HRP20140665T1 (enExample)
IL (3) IL207295A (enExample)
JO (1) JOP20090061B1 (enExample)
MX (2) MX2010008816A (enExample)
NZ (4) NZ603958A (enExample)
PL (3) PL2249859T3 (enExample)
PT (3) PT2249859E (enExample)
RU (2) RU2504394C2 (enExample)
SI (3) SI2249859T1 (enExample)
TW (2) TWI442932B (enExample)
WO (2) WO2009101530A1 (enExample)
ZA (1) ZA201005697B (enExample)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0117057D0 (en) * 2001-07-12 2001-09-05 Ferring Bv Pharmaceutical composition
JO3525B1 (ar) * 2008-02-11 2020-07-05 Ferring Int Center Sa علاج سرطان البروستاتا في المرحلة النقيلية بدواء ديجاريليكس
TWI442932B (zh) 2008-02-11 2014-07-01 Ferring Int Ct Sa 以ＧｎＲＨ拮抗劑治療攝護腺癌的方法
AU2010243273B2 (en) 2009-05-01 2016-06-16 Ferring B.V. Composition for the treatment of prostate cancer
TW201043221A (en) * 2009-05-06 2010-12-16 Ferring Int Ct Sa Kit and method for preparation of a Degarelix solution
US20110039787A1 (en) * 2009-07-06 2011-02-17 Ferring International Center S.A. Compositions, kits and methods for treating benign prostate hyperplasia
FR2964323B1 (fr) * 2010-09-08 2012-11-09 Jean Pierre Raynaud Utilisation de la testosterone chez un patient en deficit androgenique et atteint d'un cancer de la prostate
HRP20161746T1 (hr) 2010-10-27 2017-02-10 Ferring B.V. Postupak za proizvodnju degareliksa i njegovih međuprodukata
EP2447276A1 (en) 2010-10-27 2012-05-02 Ferring B.V. Process for the manufacture of Degarelix and its intermediates
JO3755B1 (ar) 2011-01-26 2021-01-31 Ferring Bv تركيبات تستوستيرون
DK2683643T3 (da) 2011-03-09 2019-08-12 Richard G Pestell Prostatacancercellelinjer, gensignaturer og anvendelser deraf
CN102204889B (zh) * 2011-05-23 2013-09-18 蚌埠丰原涂山制药有限公司 一种醋酸地加瑞克冻干粉针剂及其制备方法
WO2013104745A1 (en) * 2012-01-13 2013-07-18 Ferring Bv Pharmaceutical composition
CN104853806A (zh) 2012-05-14 2015-08-19 理查德·G·佩斯泰尔 使用ccr5调节剂治疗癌症
FI4512390T1 (fi) 2012-06-01 2025-08-01 Ferring Bv Degareliksin valmistaminen
ES2836424T3 (es) 2012-09-26 2021-06-25 Aragon Pharmaceuticals Inc Antiandrógenos para tratar el cáncer de próstata no metastásico y resistente a la castración
RS58703B1 (sr) 2012-09-28 2019-06-28 Takeda Pharmaceuticals Co Metoda proizvodnje derivata tienopirimidina
IL241595B2 (en) 2013-03-15 2025-10-01 Abbvie Inc Composition for use in methods of treating heavy menstrual bleeding associated with uterine fibroids
WO2014186608A1 (en) * 2013-05-15 2014-11-20 Adverse Events, Inc. System and method for surveillance and evaluation of safety risks associated with medical interventions
EP3185881B1 (en) * 2014-08-26 2022-03-09 Betanien Hospital Methods, agents and compositions for treatment of inflammatory conditions
AU2016261770B2 (en) * 2015-05-12 2022-06-02 Drexel University Compounds and compositions useful for treating or preventing cancer metastasis, and methods using same
WO2018060463A2 (en) 2016-09-30 2018-04-05 Myovant Sciences Gmbh Treatment of prostate cancer
BR112019014192A2 (pt) * 2017-01-30 2020-02-11 Antev Limited Composição compreendendo pelo menos um antagonista de gnrh
UA129105C2 (uk) 2017-10-16 2025-01-15 Арагон Фармасьютикалз, Інк. Антиандрогени для лікування неметастатичного резистентного до кастрації раку передміхурової залози
BR112020021276A2 (pt) 2018-04-19 2021-01-26 Abbvie Inc. métodos de tratamento de sangramento menstrual intenso
CA3107597A1 (en) * 2018-08-01 2020-02-06 Abbvie Inc. Dosing regimens for elagolix
RU2731002C1 (ru) * 2019-10-22 2020-08-26 Государственное бюджетное учреждение здравоохранения Московской области "Московский областной научно-исследовательский клинический институт им. М.Ф. Владимирского" (ГБУЗ МО МОНИКИ им. М.Ф. Владимирского) Способ лечения рака предстательной железы
CN116407494B (zh) * 2023-03-02 2024-07-09 山东大学齐鲁医院 一种醋酸地加瑞克注射液及其制备方法、用途

Family Cites Families (57)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
ZA735680B (en) * 1972-09-21 1974-07-31 Hoffmann La Roche Polypeptides
US4072668A (en) 1973-11-06 1978-02-07 The Salk Institute For Biological Studies LH-RH Analogs
EP0002749B2 (en) 1977-12-26 1987-08-12 IHARA CHEMICAL INDUSTRY Co., Ltd. Process for producing aromatic monocarboxylic acid
US5296468A (en) 1989-10-30 1994-03-22 The Salk Institute For Biological Studies GnRH analogs
ES2052488T3 (es) 1991-04-25 1997-01-01 Romano Deghenghi Peptidos antagonistas de la hormona de liberacion de la hormona luteinizante.
DK0556034T4 (da) 1992-02-12 2004-11-15 Daikyo Gomu Seiko Kk Et medicinsk instrument
GB9211268D0 (en) * 1992-05-28 1992-07-15 Ici Plc Salts of basic peptides with carboxyterminated polyesters
SI9300468A (en) 1992-10-14 1994-06-30 Hoffmann La Roche Injectable composition for the sustained release of biologically active compounds
DE4305225A1 (de) * 1993-02-19 1994-08-25 Asta Medica Ag Neues Herstellverfahren für Cetrorelix Lyophilisat
US5506207A (en) 1994-03-18 1996-04-09 The Salk Institute For Biological Studies GNRH antagonists XIII
US5595760A (en) 1994-09-02 1997-01-21 Delab Sustained release of peptides from pharmaceutical compositions
JP3688381B2 (ja) 1995-03-10 2005-08-24 株式会社東芝 光ディスク原盤露光装置
US6379669B1 (en) 1995-08-04 2002-04-30 Akhouri A. Sinha Targeting of organs by immunoconjugates
US5710246A (en) 1996-03-19 1998-01-20 Abbott Laboratories Process for intermediates for the synthesis of LHRH antagonists
US5860957A (en) 1997-02-07 1999-01-19 Sarcos, Inc. Multipathway electronically-controlled drug delivery system
US5821230A (en) * 1997-04-11 1998-10-13 Ferring Bv GnRH antagonist decapeptides
US5925730A (en) 1997-04-11 1999-07-20 Ferring Bv GnRH antagonists
WO1999026964A1 (en) 1997-11-20 1999-06-03 Ortho-Mcneil Pharmaceutical, Inc. LIQUID PHASE PROCESS FOR THE PREPARATION OF GnRH PEPTIDES
FR2776520B1 (fr) 1998-03-25 2000-05-05 Sod Conseils Rech Applic Nouvelles compositions pharmaceutiques destinees a la liberation prolongee de peptides et leur procede de preparation
MXPA01000674A (es) 1998-07-20 2002-04-08 Peptech Ltd Formulacion de bioimplante.
MXPA02008870A (es) * 2000-03-14 2003-06-24 Zentaris Ag Novedosos antagonistas de lhrh, produccion de los mismos y sus uso como medicamentos.
US20040198706A1 (en) 2003-03-11 2004-10-07 Carrara Dario Norberto R. Methods and formulations for transdermal or transmucosal application of active agents
US20020103131A1 (en) 2001-01-26 2002-08-01 Jacobson Jill D. Prevention of diabetes by administration of GnRH antagonists
JP4619651B2 (ja) * 2001-06-01 2011-01-26 コーネル・リサーチ・ファンデーション・インコーポレイテッド 前立腺特異的膜抗原に対する修飾抗体およびその使用
GB0117057D0 (en) 2001-07-12 2001-09-05 Ferring Bv Pharmaceutical composition
US7229774B2 (en) 2001-08-02 2007-06-12 Regents Of The University Of Michigan Expression profile of prostate cancer
US20070015713A1 (en) 2005-07-14 2007-01-18 Voyager Pharmaceutical Corporation Methods for treating prostate cancer
US20060234918A1 (en) * 2001-12-19 2006-10-19 Voyager Pharmaceutical Corporation Methods for treating and preventing cancers that express the hypothalamic-pituitary-gonadal axis of hormones and receptors
SE0104463D0 (sv) 2001-12-29 2001-12-29 Carlbiotech Ltd As Mellanprodukter för syntes af LHRH-antagonister, sätt att framställa dem och sätt för framställning av LHRH-antagonister
CN1411803A (zh) 2002-08-29 2003-04-23 四川大学 制备前体脂质体的方法及其装置
NZ538928A (en) 2002-09-27 2006-10-27 Zentaris Gmbh Administration form for pharmaceutically active peptides with sustained release of active ingredient, and method for the production thereof
GB0223367D0 (en) * 2002-10-09 2002-11-13 Astrazeneca Ab Therapeutic treatment
AR042815A1 (es) * 2002-12-26 2005-07-06 Alza Corp Dispositivo de suministro de agente activo que tiene miembros compuestos
EP1674082A1 (de) 2004-12-22 2006-06-28 Zentaris GmbH Verfahren zur Herstellung von sterilen Suspensionen oder Lyophilisaten schwerlöslicher basischer Peptidkomplexe, diese enthaltende pharmazeutische Formulierungen sowie ihre Verwendung als Arzneimittel
WO2006069779A1 (en) 2004-12-30 2006-07-06 F. Hoffmann-La Roche Ag Preparing of peptides with excellent solubility
US8158152B2 (en) 2005-11-18 2012-04-17 Scidose Llc Lyophilization process and products obtained thereby
WO2007130809A2 (en) 2006-05-06 2007-11-15 Volodymyr Brodskyy An automatic injectable drug mixing device
EP1891964A1 (en) 2006-08-08 2008-02-27 AEterna Zentaris GmbH Application of initial doses of LHRH analogues and maintenance doses of LHRH antagonists for the treatment of hormone-dependent cancers and corresponding pharmaceutical kits
EP1967202A1 (en) 2007-03-05 2008-09-10 AEterna Zentaris GmbH Use of LHRH Antagonists for the Treatment of Lower Urinary Tract Symptoms, in particular Overactive Bladder and/or Detrusor Overactivity
IL182922A0 (en) 2007-05-02 2007-09-20 Medimop Medical Projects Ltd Automatic liquid drug reconstitution apparatus
US8283331B2 (en) 2007-10-09 2012-10-09 Children's Medical Center Corporation Methods to regulate miRNA processing by targeting Lin-28
WO2009090189A1 (en) 2008-01-15 2009-07-23 Abbott Gmbh & Co.Kg Powdered protein compositions and methods of making same
EP2257324B1 (en) 2008-02-11 2016-07-27 Safety Syringes, Inc. Syringe with safety needle guard and clip to prevent release of guard during reconstitution process
TWI442932B (zh) 2008-02-11 2014-07-01 Ferring Int Ct Sa 以ＧｎＲＨ拮抗劑治療攝護腺癌的方法
ES2538828T3 (es) 2009-04-24 2015-06-24 Polypeptide Laboratories A/S Método para la fabricación de degarelix
AU2010243273B2 (en) 2009-05-01 2016-06-16 Ferring B.V. Composition for the treatment of prostate cancer
TW201043221A (en) 2009-05-06 2010-12-16 Ferring Int Ct Sa Kit and method for preparation of a Degarelix solution
US20110039787A1 (en) 2009-07-06 2011-02-17 Ferring International Center S.A. Compositions, kits and methods for treating benign prostate hyperplasia
WO2011066386A1 (en) 2009-11-25 2011-06-03 Novetide, Ltd. Process for production of degarelix
ES2385240B1 (es) 2010-07-26 2013-09-23 Gp-Pharm, S.A. Cápsulas de principios activos farmacéuticos y ácidos grasos poliinsaturados para el tratamiento de enfermedades de la próstata.
HRP20161746T1 (hr) 2010-10-27 2017-02-10 Ferring B.V. Postupak za proizvodnju degareliksa i njegovih međuprodukata
EP2447276A1 (en) 2010-10-27 2012-05-02 Ferring B.V. Process for the manufacture of Degarelix and its intermediates
JO3755B1 (ar) 2011-01-26 2021-01-31 Ferring Bv تركيبات تستوستيرون
CN102204889B (zh) 2011-05-23 2013-09-18 蚌埠丰原涂山制药有限公司 一种醋酸地加瑞克冻干粉针剂及其制备方法
EP3269368A1 (en) 2011-07-15 2018-01-17 Ferring B.V. Method for timing a colonoscopy wherein a picosulfate composition is administered
FI4512390T1 (fi) 2012-06-01 2025-08-01 Ferring Bv Degareliksin valmistaminen

Also Published As

Publication number Publication date
WO2009101530A1 (en) 2009-08-20
US9415085B2 (en) 2016-08-16
US20220031801A1 (en) 2022-02-03
EP2249859A1 (en) 2010-11-17
BRPI0908127A2 (pt) 2015-08-04
US8841081B2 (en) 2014-09-23
KR20140130757A (ko) 2014-11-11
US20200237854A1 (en) 2020-07-30
US20210128673A1 (en) 2021-05-06
AU2009213751A1 (en) 2009-08-20
BRPI0908129A2 (pt) 2015-08-04
DK2650012T3 (da) 2015-06-15
US10973870B2 (en) 2021-04-13
MX2010008817A (es) 2010-09-09
TW200938217A (en) 2009-09-16
RU2010133480A (ru) 2012-03-20
IL207295A (en) 2015-03-31
IL207295A0 (en) 2010-12-30
JP2022133426A (ja) 2022-09-13
JP2011511786A (ja) 2011-04-14
NZ603958A (en) 2013-03-28
IL223124A0 (en) 2012-12-31
PL2505204T3 (pl) 2015-05-29
US11766468B2 (en) 2023-09-26
US10695398B2 (en) 2020-06-30
EP2799085A1 (en) 2014-11-05
JP2016193910A (ja) 2016-11-17
JP2011511785A (ja) 2011-04-14
EP2650012A1 (en) 2013-10-16
EP2249859B1 (en) 2014-04-23
CN103990107A (zh) 2014-08-20
EP4257197A3 (en) 2023-11-29
KR20100123714A (ko) 2010-11-24
MX2010008816A (es) 2010-09-07
US10729739B2 (en) 2020-08-04
PT2505204E (pt) 2015-03-26
CA2714444A1 (en) 2009-08-20
CA2714445C (en) 2018-01-16
NZ587088A (en) 2012-12-21
JP6618967B2 (ja) 2019-12-11
US20220323538A1 (en) 2022-10-13
RU2010133481A (ru) 2012-03-20
EP2505204B1 (en) 2014-12-24
AU2009213751B2 (en) 2014-09-25
DK2249859T3 (da) 2014-06-02
HK1176552A1 (en) 2013-08-02
US20220218782A1 (en) 2022-07-14
PT2650012E (pt) 2015-06-30
RU2504394C2 (ru) 2014-01-20
HK1198243A1 (en) 2015-03-20
JP2018039814A (ja) 2018-03-15
JP2016216455A (ja) 2016-12-22
EP3360565A1 (en) 2018-08-15
CN101939020A (zh) 2011-01-05
EA017582B1 (ru) 2013-01-30
CA2714445A1 (en) 2009-08-20
CN101998861A (zh) 2011-03-30
US20140349935A1 (en) 2014-11-27
JP2014141505A (ja) 2014-08-07
IL207400A (en) 2014-12-31
ES2540235T3 (es) 2015-07-09
TWI539959B (zh) 2016-07-01
PL2650012T3 (pl) 2015-08-31
IL207400A0 (en) 2010-12-30
PL2249859T3 (pl) 2014-10-31
JP5924866B2 (ja) 2016-05-25
JP2025160167A (ja) 2025-10-22
SI2249859T1 (sl) 2014-08-29
JP2024028869A (ja) 2024-03-05
JP6189234B2 (ja) 2017-08-30
EA020543B1 (ru) 2014-12-30
HRP20140665T1 (hr) 2014-10-10
SI2505204T1 (sl) 2015-04-30
KR20220009504A (ko) 2022-01-24
HK1145011A1 (en) 2011-03-25
KR20230088848A (ko) 2023-06-20
CN101939020B (zh) 2012-12-26
US9579359B2 (en) 2017-02-28
CA3235099A1 (en) 2009-08-20
AU2009213748A1 (en) 2009-08-20
US20090203623A1 (en) 2009-08-13
EA036695B1 (ru) 2020-12-09
KR20250028541A (ko) 2025-02-28
PT2249859E (pt) 2014-07-31
AU2009213748B2 (en) 2014-03-13
KR20100126362A (ko) 2010-12-01
US20130029910A1 (en) 2013-01-31
JP5876652B2 (ja) 2016-03-02
US11826397B2 (en) 2023-11-28
CY1116289T1 (el) 2017-02-08
EP2505204A2 (en) 2012-10-03
ES2532709T3 (es) 2015-03-31
EA026521B1 (ru) 2017-04-28
JP2014167009A (ja) 2014-09-11
JOP20090061B1 (ar) 2021-08-17
KR101542480B1 (ko) 2015-08-07
US20170290879A1 (en) 2017-10-12
US20170035833A1 (en) 2017-02-09
KR20150091543A (ko) 2015-08-11
US20250134948A1 (en) 2025-05-01
ZA201005697B (en) 2014-01-24
TW200938218A (en) 2009-09-16
US20220226422A1 (en) 2022-07-21
ES2479441T3 (es) 2014-07-24
EP2249858A1 (en) 2010-11-17
US20240316142A1 (en) 2024-09-26
SI2650012T1 (sl) 2015-06-30
TWI442932B (zh) 2014-07-01
RU2504393C2 (ru) 2014-01-20
CY1115561T1 (el) 2017-01-04
HRP20150290T1 (hr) 2015-04-10
JP6254042B2 (ja) 2017-12-27
EP2650012B1 (en) 2015-03-25
EP4257197A2 (en) 2023-10-11
HK1190912A1 (en) 2014-07-18
US20220218783A1 (en) 2022-07-14
WO2009101533A1 (en) 2009-08-20
CN107412726A (zh) 2017-12-01
NZ603932A (en) 2014-04-30
US9877999B2 (en) 2018-01-30
KR20180118830A (ko) 2018-10-31
JP2022184898A (ja) 2022-12-13
US20090203622A1 (en) 2009-08-13
EA201300742A1 (ru) 2014-02-28
JP7400029B2 (ja) 2023-12-18
NZ587057A (en) 2012-12-21
EA200901075A1 (ru) 2010-04-30
US20190167755A1 (en) 2019-06-06
AU2009213748B9 (en) 2014-05-22
US20140113870A1 (en) 2014-04-24
HRP20150633T1 (hr) 2015-07-31
CY1116341T1 (el) 2017-02-08
EP2505204A3 (en) 2013-01-09
EA201300741A1 (ru) 2014-02-28
EA200901074A1 (ru) 2010-04-30

Similar Documents

Publication Publication Date Title
DK2505204T3 (da) Fremgangsmåde til behandling af prostatakræft med GnRH-antagonisten degarelix
BRPI0913879A2 (pt) fenilpirazinonas como inibidores de quinase
BRPI0912317A2 (pt) método de autenticação
BRPI0920135A2 (pt) imidazopiridazinacarbonitrilos úteis como inibidores de quinase
BRPI0907928A2 (pt) Inibidores de pirrolopirazina quinase.
BRPI0908494A2 (pt) Inibidores de pirrolopirazina quinase
DK2440545T3 (da) Forbindelser, der er anvendelige til behandling af cancer
BRPI0913580A2 (pt) pirrolopiridinas como inibidores de quinase
DK2310034T3 (da) Peptider til behandling af beta-amyloidose
EP2515657A4 (en) Tyrosine kinase inhibitor
BRPI0906838A2 (pt) Pirimidinas como inibidores de quinase
LT2313364T (lt) Simetrinio dimetilarginino nustatymo būdai
BR112012002797A2 (pt) tratamento de câncer de próstata
DK3106874T3 (da) Fremgangsmåde til detektering af cancer
DK2318378T3 (da) Quinazolin-derivater
DK2310613T3 (da) Forbedret brudled til stigrør
EP2435048A4 (en) RADIOACTIVELY MARKED PDE10 HEMMER
BRPI0914936A2 (pt) naftiridininonas como inibidores de aurora quinase
BRPI0924067A2 (pt) compostos de quinazolina substituída
BRPI0716198A2 (pt) Pirrolo-isoquinolinas como inibidores de cinase
ZA201008177B (en) Substituted quinazolines
DK2124547T6 (da) Fremgangsmåde til behandling af cancer
GB0808944D0 (en) Substituted quinazolines
BR112012010524A2 (pt) compostos derivados de quinazolina
DK2272538T3 (da) Fremgangsmåde til påvisning af blærecancer